Personalized for the most deadly type of brain tumor vaccine shows promise

History showed itself from the patients with treatment of patients with recurrent glioblastoma made an experimental vaccine (GBM) resection tumor survival rates improve, alone, received the standard care patients compared to this vaccine has been published in the journal of neuro-oncology, accompanied by an editorial to emphasize the importance of the trial phase 2 according to the analysis of the test. Phase 2 trials, Northwestern Feinberg School and the Robert H. Lurie Comprehensive Cancer Center enrolled 41 conducted by adult recurrent tumor cases 2007-2011, from the researchers.

View the original article here